Patents by Inventor Shengwen Li

Shengwen Li has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Modified Clostridial toxins with enhanced targeting capabilities for endogenous Clostridial toxin receptor systems
    Patent number: 8623999
    Abstract: The specification discloses modified Clostridial toxins comprising a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and an enhanced Clostridial toxin binding domain; polynucleotide molecules encoding such modified Clostridial toxins; and method of producing such modified Clostridial toxins.
    Type: Grant
    Filed: February 27, 2012
    Date of Patent: January 7, 2014
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Joseph Francis, Shengwen Li, Marcella A. Gilmore, Kei Roger Aoki
  • MODIFIED CLOSTRIDIAL TOXINS WITH ENHANCED TRANSLOCATION CAPABILITIY
    Publication number: 20130345413
    Abstract: The specification discloses modified Clostridial toxins comprising a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain, a translocation facilitating domain and an enhanced targeting domain; polynucleotide molecules encoding such modified Clostridial toxins; and method of producing such modified Clostridial toxins.
    Type: Application
    Filed: August 20, 2013
    Publication date: December 26, 2013
    Applicant: Allergan, Inc.
    Inventors: Lance E. Steward, Joseph Francis, Ester Fernandez-Salas, Marcella A. Gilmore, Shengwen Li
  • Modified clostridial toxins with enhanced translocation capability and enhanced targeting activity
    Patent number: 8518417
    Abstract: The specification discloses modified Clostridial toxins comprising a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain, a translocation facilitating domain and an enhanced targeting domain; polynucleotide molecules encoding such modified Clostridial toxins; and method of producing such modified Clostridial toxins.
    Type: Grant
    Filed: July 11, 2007
    Date of Patent: August 27, 2013
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Joseph Francis, Ester G. Fernandez-Salas, Marcella A. Gilmore, Shengwen Li, Kei Roger Aoki
  • MODIFIED CLOSTRIDIAL TOXINS WITH ENHANCED TRANSLOCATION CAPABILITY AND ENHANCED TARGETING ACTIVITY
    Publication number: 20130203148
    Abstract: The specification discloses modified Clostridial toxins comprising a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain, a translocation facilitating domain and an enhanced targeting domain; polynucleotide molecules encoding such modified Clostridial toxins; and method of producing such modified Clostridial toxins.
    Type: Application
    Filed: July 11, 2007
    Publication date: August 8, 2013
    Inventors: Lance E. Steward, Joseph Francis, Ester G. Fernandez-Salas, Marcella A. Gilmore, Shengwen Li, Kei Roger Aoki
  • Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
    Patent number: 8460682
    Abstract: The specification discloses modified Clostridial toxins comprising a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and an enhanced Clostridial toxin binding domain; polynucleotide molecules encoding such modified Clostridial toxins; and method of producing such modified Clostridial toxins.
    Type: Grant
    Filed: October 26, 2011
    Date of Patent: June 11, 2013
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Joseph Francis, Shengwen Li, Marcella A. Gilmore, Kei Roger Aoki
  • Multivalent clostridial toxins
    Patent number: 8273865
    Abstract: The present invention is directed to multivalent Clostridial toxin comprising more than one binding domain directed to a cell surface molecule of a target cell. Such modified toxins are useful as therapeutic compositions to prevent exocytosis and secretion by the target cell. Conditions in which such compositions may be useful include, without limitation, disorders of the sensory or motor nervous system, acute or chronic pain, cancer, pancreatitis, hyperhydrosis, glandular disorders, viral infections, cystic fibrosis and the like. The invention is also directed to methods of using and administering such a composition, and methods of treating a given condition using such a composition.
    Type: Grant
    Filed: September 16, 2010
    Date of Patent: September 25, 2012
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Joseph Francis, Shengwen Li, Marcella A. Gilmore, Kei Roger Aoki
  • Activatable clostridial toxins
    Patent number: 8273358
    Abstract: Compositions comprising activatable recombinant neurotoxins and polypeptides derived therefrom. The invention also comprises nucleic acids encoding such polypeptides, and methods of making such polypeptides and nucleic acids.
    Type: Grant
    Filed: August 15, 2008
    Date of Patent: September 25, 2012
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Joseph Francis, Ester Fernandez-Salas, Sanjiv Ghanshani, Marcella A. Gilmore, Shengwen Li, J. Oliver Dolly, Kei Roger Aoki
  • Modified Clostridial Toxins with Enhanced Targeting Capabilities For Endogenous Clostridial Toxin Receptor Systems
    Publication number: 20120178140
    Abstract: The specification discloses modified Clostridial toxins comprising a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and an enhanced Clostridial toxin binding domain; polynucleotide molecules encoding such modified Clostridial toxins; and method of producing such modified Clostridial toxins.
    Type: Application
    Filed: February 27, 2012
    Publication date: July 12, 2012
    Applicant: ALLERGAN, INC.
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Joseph Francis, Shengwen Li, Marcella A. Gilmore, Kei Roger Aoki
  • Organotypic slices of the central nervous system
    Patent number: 8198083
    Abstract: An organotypic slice and a method of preparing an organotypic slice from a central nervous system tissue, wherein the organotypic slice comprises a brain slice obtained from a brain wherein mature synapses have not been established and the organotypic slice is seeded with a population of stem cells; wherein the organotypic slice has enhanced viability as compared to an organotypic slice comprising a similar brain slice not seeded with a population of stem cells.
    Type: Grant
    Filed: October 31, 2008
    Date of Patent: June 12, 2012
    Inventors: William Gunter Loudon, Shengwen Li, Brent A. Dethlefs
  • Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems
    Patent number: 8128940
    Abstract: The specification discloses modified Clostridial toxins comprising a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and an enhanced Clostridial toxin binding domain; polynucleotide molecules encoding such modified Clostridial toxins; and method of producing such modified Clostridial toxins.
    Type: Grant
    Filed: March 14, 2006
    Date of Patent: March 6, 2012
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Joseph Francis, Shengwen Li, Marcella A. Gilmore, Kei R. Aoki
  • Modified Clostridial Toxins with Altered Targeting Capabilities For Clostridial Toxin Target Cells
    Publication number: 20120052548
    Abstract: The specification discloses modified Clostridial toxins comprising a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and an enhanced Clostridial toxin binding domain; polynucleotide molecules encoding such modified Clostridial toxins; and method of producing such modified Clostridial toxins.
    Type: Application
    Filed: October 26, 2011
    Publication date: March 1, 2012
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Joseph Francis, Shengwen Li, Marcella A. Gilmore, Kei Roger Aoki
  • Activatable clostridial toxins
    Patent number: 8071110
    Abstract: Compositions comprising activatable recombinant neurotoxins and polypeptides derived therefrom. The invention also comprises nucleic acids encoding such polypeptides, and methods of making such polypeptides and nucleic acids.
    Type: Grant
    Filed: August 15, 2008
    Date of Patent: December 6, 2011
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Joseph Francis, Ester Fernandez-Salas, Sanjiv Ghanshani, Marcella A. Gilmore, Shengwen Li, J. Oliver Dolly, Kei Roger Aoki
  • DEGRADABLE CLOSTRIDIAL TOXINS
    Publication number: 20110294742
    Abstract: The specification discloses modified Clostridial toxins comprising a PAR ligand domain, a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and a Clostridial toxin binding domain; polynucleotide molecules encoding modified Clostridial toxins comprising a PAR ligand domain, a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and a Clostridial toxin binding domain; and method of producing modified Clostridial toxins comprising a PAR ligand domain, a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and a Clostridial toxin binding domain.
    Type: Application
    Filed: August 15, 2011
    Publication date: December 1, 2011
    Applicant: ALLERGAN, INC.
    Inventors: LANCE E. STEWARD, ESTER G. FERNANDEZ-SALAS, MARCELLA A. GILMORE, JOSEPH FRANCIS, SHENGWEN LI, KEI ROGER AOKI
  • Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
    Patent number: 8052979
    Abstract: The specification discloses modified Clostridial toxins comprising a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and an enhanced Clostridial toxin binding domain; polynucleotide molecules encoding such modified Clostridial toxins; and method of producing such modified Clostridial toxins.
    Type: Grant
    Filed: March 14, 2006
    Date of Patent: November 8, 2011
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Joseph Francis, Shengwen Li, Marcella A. Gilmore, Kei Roger Aoki
  • Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
    Patent number: 8021859
    Abstract: The specification discloses modified Clostridial toxins comprising a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and an enhanced Clostridial toxin binding domain; polynucleotide molecules encoding such modified Clostridial toxins; and method of producing such modified Clostridial toxins.
    Type: Grant
    Filed: August 15, 2008
    Date of Patent: September 20, 2011
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Joseph Francis, Shengwen Li, Marcella A. Gilmore, Kei Roger Aoki
  • Degradable clostridial toxins
    Patent number: 7998489
    Abstract: The specification discloses modified Clostridial toxins comprising a PAR ligand domain, a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and a Clostridial toxin binding domain; polynucleotide molecules encoding modified Clostridial toxins comprising a PAR ligand domain, a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and a Clostridial toxin binding domain; and method of producing modified Clostridial toxins comprising a PAR ligand domain, a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and a Clostridial toxin binding domain.
    Type: Grant
    Filed: August 15, 2008
    Date of Patent: August 16, 2011
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Ester G. Fernandez-Salas, Marcella A. Gilmore, Joseph Francis, Shengwen Li, Kei Roger Aoki
  • Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells
    Patent number: 7993656
    Abstract: The invention provides modified Clostridial toxins comprising a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain, a translocation facilitating domain and an altered target domain; polynucleotide molecules encoding such modified Clostridial toxins; and methods of producing such modified Clostridial toxins.
    Type: Grant
    Filed: July 11, 2007
    Date of Patent: August 9, 2011
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Joseph Francis, Ester G. Fernandez-Salas, Marcella A. Gilmore, Shengwen Li, Kei Roger Aoki
  • Optimizing Expression of Active Botulinum Toxin Type E
    Publication number: 20110111483
    Abstract: Nucleic acid molecules that comprise modified open reading frames providing increased expression of the encoded active BoNT/E in a heterologous cell, expression constructs and cells comprising such nucleic acid molecules and methods useful for expressing the encoding active BoNT/E from such nucleic acid molecules, expression constructs and cells.
    Type: Application
    Filed: October 14, 2010
    Publication date: May 12, 2011
    Applicant: ALLERGAN, INC.
    Inventors: LANCE E. STEWARD, MARCELLA A. GILMORE, ESTER G. FERNANDEZ-SALAS, SHENGWEN LI, RONALD G. MILLER, KEI ROGER AOKI
  • Multivalent Clostridial Toxins
    Publication number: 20110070621
    Abstract: The present invention is directed to multivalent Clostridial toxin comprising more than one binding domain directed to a cell surface molecule of a target cell. Such modified toxins are useful as therapeutic compositions to prevent exocytosis and secretion by the target cell. Conditions in which such compositions may be useful include, without limitation, disorders of the sensory or motor nervous system, acute or chronic pain, cancer, pancreatitis, hyperhydrosis, glandular disorders, viral infections, cystic fibrosis and the like. The invention is also directed to methods of using and administering such a composition, and methods of treating a given condition using such a composition.
    Type: Application
    Filed: September 16, 2010
    Publication date: March 24, 2011
    Applicant: ALLERGAN, INC.
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Joseph Francis, Shengwen Li, Marcella A. Gilmore, Kei Roger Aoki
  • Activatable clostridial toxins
    Patent number: 7897157
    Abstract: Compositions comprising activatable recombinant neurotoxins and polypeptides derived therefrom. The invention also comprises nucleic acids encoding such polypeptides, and methods of making such polypeptides and nucleic acids.
    Type: Grant
    Filed: August 27, 2007
    Date of Patent: March 1, 2011
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Joseph Francis, Ester Fernandez-Salas, Sanjiv Ghanshani, Marcella A. Gilmore, Shengwen Li, J. Oliver Dolly, Kei Roger Aoki